Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-15, Stock:ABBV, The news for the past five days is as follows:
2018-11-08: NEWS1: DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS3: AbbVie Rises 3%.NEWS4: SHAREHOLDER ALERT: MCHP COCP ABBV JT TRVN SFIX CWH HON ALGN NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS5: Europe: Key Growth Driver for Mylan.NEWS6: How Analysts Rate AbbVie Stock.NEWS7: Investor Expectations to Drive Momentum within AbbVie, Ducommun, Life Storage, NMI, Church & Dwight Co., and Lumentum — Discovering Underlying Factors of Influence.NEWS8: Edited Transcript of ABBV earnings conference call or presentation 2-Nov-18 1:00pm GMT.NEWS9: 7 Healthcare Stocks Soaring on Election Results.NEWS10: 7 Healthcare Stocks Soaring on Election Results.
2018-11-09: NEWS1: Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices.NEWS2: Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3.NEWS3: Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3.NEWS4: Assessing GW Pharmaceuticals’ Year-to-Date Performance.NEWS5: 6 Pharmaceutical Stocks to Buy After the Midterms.NEWS6: 6 Pharmaceutical Stocks to Buy After the Midterms.NEWS7: Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3.NEWS8: CLASS ACTION UPDATE for ABBV, HON and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS9: Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug.NEWS10: Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug.NEWS11: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS12: AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset.NEWS13: Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug.NEWS14: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS15: AbbVie (ABBV) Gains As Market Dips: What You Should Know.
2018-11-12: NEWS1: SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS2: Why AbbVie's Stock Cratered in October.NEWS3: Why AbbVie's Stock Cratered in October.NEWS4: INVESTOR REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS5: Most Analysts Are Bullish on Nektar Stock.NEWS6: Why AbbVie&apos;s Stock Cratered in October.
2018-11-13: NEWS1: Health Care Sector Update for 11/13/2018: ABBV,VKTX,CRON,CRON.TO,VLRX.NEWS2: Health Care Sector Update for 11/13/2018: ABBV,VKTX,CRON,CRON.TO,VLRX.NEWS3: AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis.NEWS4: Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC.NEWS5: Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC.NEWS6: AbbVie to Present at the Evercore ISI Conference.NEWS7: Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC.
2018-11-14: NEWS1: MNK Awaits D-Day, AMEH In Good Health, AXSM To Report ASCEND Data In Jan..NEWS2: MNK Awaits D-Day, AMEH In Good Health, AXSM To Report ASCEND Data In Jan..NEWS3: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS4: AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress.NEWS5: AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi.NEWS6: AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi.NEWS7: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS8: AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS9: CLASS ACTION UPDATE for ABBV, CHGG and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS10: AbbVie&apos;s HCV Drug Mavyret Succeeds in Label Expansion Study.NEWS11: 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS12: November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS13: IWF, KO, PEP, ABBV: ETF Inflow Alert.NEWS14: IWF, KO, PEP, ABBV: ETF Inflow Alert.NEWS15: DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018.NEWS16: The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark.

Answer: Rise